Karyopharm Therapeut
(KPTI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 37,672 | 38,725 | 38,783 | 62,476 | 72,861 |
| Marketable Securities | 8,205 | 12,972 | 31,158 | 46,236 | 60,698 |
| Receivables | 31,877 | 32,932 | 35,243 | 30,766 | 31,778 |
| Inventories | 3,966 | 4,992 | 4,769 | 4,739 | 4,672 |
| TOTAL | $89,746 | $97,870 | $120,238 | $156,462 | $184,755 |
| Non-Current Assets | |||||
| PPE Net | 122 | 244 | 322 | 400 | 495 |
| Other Non-Current Assets | 6,364 | 6,765 | 7,151 | 7,556 | 4,226 |
| TOTAL | $6,486 | $7,009 | $7,473 | $7,956 | $4,721 |
| Total Assets | $96,232 | $104,879 | $127,711 | $164,418 | $189,476 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 12,750 | 30,734 | 24,459 | 24,426 | N/A |
| Accounts payable and accrued liabilities | 5,392 | 2,597 | 5,872 | 5,107 | 5,783 |
| Accrued Expenses | 66,328 | 62,929 | 57,172 | 60,652 | 50,105 |
| Other current liabilities | 1,765 | 1,573 | 1,940 | 1,641 | 1,937 |
| TOTAL | $87,157 | $99,216 | $90,370 | $92,264 | $61,493 |
| Non-Current Liabilities | |||||
| Long Term Debt | 83,895 | 89,566 | 95,197 | 94,603 | 94,109 |
| Other Non-Current Liabilities | 194,438 | 155,023 | 148,028 | 163,568 | 193,521 |
| TOTAL | $278,333 | $244,589 | $243,225 | $258,171 | $287,630 |
| Total Liabilities | $365,490 | $343,805 | $333,595 | $350,435 | $349,123 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,051 | 8,671 | 8,640 | 8,420 | 8,358 |
| Common Shares | 13 | 13 | 13 | 13 | 13 |
| Retained earnings | -1,657,301 | -1,624,174 | -1,586,922 | -1,563,460 | -1,532,680 |
| Other shareholders' equity | -259 | -251 | -321 | -356 | -222 |
| TOTAL | $-269,258 | $-238,926 | $-205,884 | $-186,017 | $-159,647 |
| Total Liabilities And Equity | $96,232 | $104,879 | $127,711 | $164,418 | $189,476 |